Core Insights - The stock price of Sinocare Inc. (02591) increased by 5.37%, currently trading at HKD 32.60, with a transaction volume of HKD 33.25 million [1][4] - The first domestically developed ultra-long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing®), has been officially included in the 2025 National Medical Insurance Drug List, effective from January 1, 2026, aimed at controlling blood sugar in adult patients with type 2 diabetes [1][4] - This inclusion marks a significant step towards the accessibility of innovative diabetes treatments in China, aligning with the "Healthy China 2030" initiative [1][4] Industry Developments - The National Guidelines for Diabetes Prevention and Control (2025) have classified Icosapent Ethyl as a GLP-1 receptor agonist injectable, providing direct policy and regulatory support for its use in primary healthcare institutions [1][4] - The guidelines emphasize the importance of GLP-1 receptor agonists as a treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those requiring weight management [1][4]

Group 1 - The Hang Seng Index fell by 0.43%, down 109 points, closing at 25,324 points, while the Hang Seng Tech Index decreased by 0.68% [1] - Lithium carbonate futures for the 2605 contract rose over 3%, reaching a peak of 96,800 yuan/ton, leading to gains in lithium stocks such as Ganfeng Lithium, which increased by 3.16%, and Tianqi Lithium, which rose by over 2% [1] - China Molybdenum's stock price increased by over 5% as CICC remains optimistic about the tungsten price bull market [2] Group 2 - Silver Star Pharmaceuticals-B surged over 18% after the company successfully entered the insurance market with its GLP-1 receptor agonist, Eino Light® [3] - Gold stocks generally rose, with Zijin Mining International increasing by over 4% and Lingbao Gold rising by 9%, supported by a strong gold market ahead of the Federal Reserve's decision [3] - Baoji Pharmaceutical-B debuted with a significant increase of 124% on its first trading day, with three core products set to be commercialized soon [4] Group 3 - China Boton saw its stock price rise by over 13% after signing a land acquisition agreement, which will provide cash compensation of 2.272 billion yuan [5] - Red Star Macalline's stock increased by over 6% as the company deepens strategic cooperation with Zuo You Home to explore new retail transformation paths [6] - China Metallurgical Group's stock continued to decline by 3.72%, following a significant drop of over 21% the previous day after announcing plans to sell assets worth 60.7 billion yuan [7] Group 4 - Pacific Basin Shipping's stock fell by over 9% as the Baltic Dry Index dropped to a near two-week low [8] - Smoore International's stock decreased by over 8%, having halved from its year-to-date high, as major client British American Tobacco forecasted performance pressures for the next year [9]